Effect of Diltiazem, a Moderate CYP3A Inhibitor, on the Pharmacokinetics of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein Inhibitor, in Healthy Subjects

被引：15
|
作者：
Garg, Amit [1 ]
Maes, Andrea [1 ]
Corr, Christy [1 ]
Jin, Bo [1 ]
Wadhwa, Tarun [1 ]
Handa, Nikhil [1 ]
Van Dyck, Kristien [1 ]
De Lepeleire, Inge [1 ]
Shah, Jinesh [2 ]
Wagner, John A. [1 ]
Krishna, Rajesh [1 ]
机构：
[1] Merck & Co Inc, Whitehouse Stn, NJ USA
[2] Veeda Clin Res, Ahmadabad, Gujarat, India
来源：
JOURNAL OF CLINICAL PHARMACOLOGY | 2011年 / 51卷 / 03期
关键词：
Cholesteryl ester transfer protein inhibition; CYP3A; diltiazem; CETP INHIBITOR; DRUG-INTERACTION; BLOOD-PRESSURE; 3A ACTIVITY; MIDAZOLAM;
D O I：
10.1177/0091270010368676
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
[No abstract available]
引用
收藏
页码：436 / 439
页数：4
相关论文
共 50 条
  • [31] EFFICACY AND SAFETY OF THE CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITOR ANACETRAPIB AS MONOTHERAPY AND COADMINISTERED WITH ATORVASTATIN IN JAPANESE PATIENTS WITH DYSLIPIDEMIA
    Numaguchi, Hirotaka
    Shirakawa, Masayoshi
    Kikuchi, Masashi
    Nakagomi, Mariko
    Sisk, Christine McCrary
    Tamura, Satoko
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 59 (13) : E1689 - E1689
  • [32] Disposition into Adipose Tissue Determines Accumulation and Elimination Kinetics of the Cholesteryl Ester Transfer Protein Inhibitor Anacetrapib in Mice
    Hartmann, Georgy
    Kumar, Sanjeev
    Johns, Douglas
    Gheyas, Ferdous
    Gutstein, David
    Shen, Xiaolan
    Burton, Aimee
    Lederman, Harmony
    Lutz, Ryan
    Jackson, Tonya
    Chavez-Eng, Cynthia
    Mitra, Kaushik
    DRUG METABOLISM AND DISPOSITION, 2016, 44 (03) : 428 - 434
  • [33] Quantitative Prediction of Human Pharmacokinetics and Pharmacodynamics of CKD519, a Potent Inhibitor of Cholesteryl Ester Transfer Protein (CETP)
    Choi, Suein
    Han, Seunghoon
    Jeon, Sangil
    Yim, Dong-Seok
    PHARMACEUTICS, 2019, 11 (07)
  • [34] Anacetrapib, a cholesterol ester transfer protein (CETP) inhibitor for treatment of atherosclerosis
    Masson, David
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2009, 10 (09) : 980 - 987
  • [35] Effect of aprepitant, a moderate CYP3A4 inhibitor, on bosutinib exposure in healthy subjects
    Poe-Hirr Hsyu
    Daniela Soriano Pignataro
    Kyle Matschke
    European Journal of Clinical Pharmacology, 2017, 73 : 49 - 56
  • [36] Effect of aprepitant, a moderate CYP3A4 inhibitor, on bosutinib exposure in healthy subjects
    Hsyu, Poe-Hirr
    Pignataro, Daniela Soriano
    Matschke, Kyle
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 73 (01) : 49 - 56
  • [37] Single dose pharmacokinetics, pharmacodynamics, tolerability and safety of BAY 60-5521, a potent inhibitor of cholesteryl ester transfer protein
    Boettcher, Michael-Friedrich
    Heinig, Roland
    Schmeck, Carsten
    Kohlsdorfer, Christian
    Ludwig, Matthias
    Schaefer, Anja
    Gelfert-Peukert, Sabine
    Wensing, Georg
    Weber, Olaf
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 73 (02) : 210 - 218
  • [38] Changes in LDL particle concentrations after treatment with the cholesteryl ester transfer protein inhibitor anacetrapib alone or in combination with atorvastatin
    Krauss, Ronald M.
    Pinto, Cathy Anne
    Liu, Yang
    Johnson-Levonas, Amy O.
    Dansky, Hayes M.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2015, 9 (01) : 93 - 102
  • [39] Impact of drug distribution into adipose on tissue function: The cholesteryl ester transfer protein (CETP) inhibitor anacetrapib as a test case
    Johns, Douglas G.
    Wang, Sheng-Ping
    Rosa, Raymond
    Hubert, James
    Xu, Suoyu
    Chen, Ying
    Bateman, Thomas
    Blaustein, Robert O.
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2019, 7 (06):
  • [40] Effect of a potent CYP3A inhibitor ketoconazole on interindividual variability of CYP3A activity as measured by oral midazolam.
    Bertino, JS
    Chen, M
    Nafziger, AN
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (02) : P51 - P51
12345